iqvia result track full-year expect
page full analyst note may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim feb
price data may
rate updat may
currenc amount express
valuat growth profit
methodolog valu compani
iqvia formerli quintilesim result merger
quintil lead provid late-stag contract research
im health domin player healthcar data analyt
combin firm unparallel scale reput support
develop commerci believ iqvia
remain leader nich space forese futur
outsourc drug
compani global scale comprehens data set enhanc
abil attract retain healthcar custom throughout
life cycl drug product im busi compil data
sourc includ pharmaci medic claim
electron health record access million
patient record unmatch data set coupl overlay
proprietari methodolog technolog enabl client set
inform strategi effect commerci drug
im data well-embed process mani
custom includ larg compani healthcar
sector result busi command price premium
high retent rate exist client
iqvia contract research organ busi leader
right -- firm late-stag sale doubl
next largest competitor -- unlimit access im global
patient data could help segment effect sourc
patient design clinic trial posit client trial
higher probabl success phase trial usual requir
thousand patient frequent take place across mani
geograph locat iqvia one
global infrastructur win contract firm size
expertis mean work clinic trial
competitor make go-to partner complic
expens project
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
iqvia creat merger healthcar data analyt
im global contract research organ powerhous
quintil cro segment focus primarili provid outsourc
phase clinic trial pharmaceut devic diagnost
compani legaci im busi provid aggreg inform
technolog servic client healthcar industri includ
pharmaceut compani provid payer policymak
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
iqvia result track full-year expect
iqvia first-quart perform fell line full-
year expect year result made
materi chang valuat model reflect
new revenu recognit account standard
increas fair valu estim iqvia per share
reflect time valu money wide-moat
rate firm intact -- believ iqvia lead
posit global late-stag contract research industri
like continu long-term thank
unmatch intang asset trial data technolog
growth across board constant currenc basi
iqvia commerci solut segment grew year
year quarter exclud impact
acquisit fall line high-single-digit
growth expect segment typic see
acceler sale back half year due
client spend pattern strong growth iqvia
technolog high-single-digit organ growth real-
compani research develop segment first-
quarter sale expand year year constant
revenu book quarter accord new
revenu recognit account standard augment
contract research busi perform think
compani gain momentum next-gener
cro solut among smaller biopharma client key
busi -- saw sale fall year year constant
currenc anticip
valuat growth profit may
rais fair valu estim wide-moat
firm per share reflect time valu
money sinc last updat fair valu estim reli
improv oper effici continu growth
im technology-servic busi call
commerci solut addit top-lin synergi
leverag data analyt effect design
clinic trial speed patient enrol cro
busi expect cro busi grow midsingl
digit next five year anticip
technolog segment see averag organ
growth period busi key
driver firm view
estim impli multipl approxim time
ep estim expect firm grow revenu
normal rate roughli
forecast period iqvia cro segment oper
highest oper margin cro space
attribut industry-lead scale legaci im
inform technolog busi boost even higher
margin creat favor product mix
compani overal forecast averag oper margin
combin compani littl
given scale client divers iqvia minim
impact singl contract loss believ firm
warrant medium uncertainti rate bull-cas
scenario assum acceler growth cro
busi thank increas outsourc penetr
effect clinic trial servic back firm
data powerhous result normal sale
growth forecast period modest margin expans
fair valu estim per share bear
scenario believ iqvia worth per share
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
sponsor pharma/biotech compani advis
help client aspect trial includ plan
size structur trial compar drug use
submit trial regulatori approv choos
geograph region investig use enrol
patient collect analyz data complet
applic regulatori approv pharma shift
outsourc clinic research project-by-project
basi partner one two handl entir
pipelin partnership led longer contract
bring deeper sponsor drug develop
process creat stickier custom higher switch
need deep scientif medic regulatori
expertis creat numer opportun add
valu drug develop process develop long-term
relationship sponsor command premium price
reput qualiti speedform foundat
moat extens data trial experi
allow firm posit client clinic trial
highest probabl success particular privi
network physician investig
pivot time trial enrol iqvia largest
provid contract research servic world
leverag data relationship gener previou
trial support clinic trial design enrol
current client firm also use unriv global
patient databas quickli identifi target patient
popul evalu trade-off clinic trial
design sponsor will pay premium increas
chanc trial get complet time
data record accur protocol
follow given signific portion drug patent live
devot clinic trial abil shave month
drug develop timelin translat
million dollar addit revenu competit
therapeut area speed drug develop
assum pharmaceut biotech firm significantli
reduc pace outsourc lead depress cro
segment growth addit fast pace technolog
servic growth slow dramat mid-singl digit
result approxim low-single-digit overal sale
growth effect merger
expertis reputationplac well ahead closest
competitor go-to partner drug develop
commerci servic compani benefit
strateg long-term relationship biopharma partner
increasingli entrench process
base behemoth scale solidifi wide moat rate
competit advantag strongest late-stag cro
market need global scale limit competit
primarili largest like iqvia given
asset-light natur late-stag cro busi
compani essenti serv consult clinic trial
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
signific determin drug ultim commerci
im health legaci busi creat wide moat
right thank
proprietari methodolog
reput high switch cost among custom
segment data compil sourc
consequ high fix acquisit cost limit
attract market new entrant
time capital-light natur busi
firm quickli scale product expand
clientel low margin cost lead high
roic breadth scale data along
firm reput provid accur complet data
creat barrier entri allow iqvia exhibit
substanti price power furthermor firm use
proprietari methodolog adjust data present
client client like stay im preserv
continu data
iqvia contract larg compani
healthcar sector reli im data develop new
product creat annual report inform sale
im data critic client busi process
discrep im data
anoth provid could neg impact
compani oper im brand name also wide
recogn respect within healthcar sector
im commonli cite reput object sourc data
annual report retent rate im top
client manag estim
averag length relationship firm top client
year
believ late-stag cro industri
competit dynam healthcar data analyt
space fundament chang assign stabl
moat trend iqvia sharp declin biopharma
research develop spend weigh
cro industri recov demand drove rapid growth
earli believ cro industri
normal state rebound growth period
book/bil backlog figur late-stag
coverag suggest industri still grow
albeit slower past new phase believ
gain strateg cro partnership biopharma
compani larg play creat oligopoli
late-stag player player round
capabl geograph expans via acquisit
expect competit dynam among shift
think iqvia data technolog segment
provid iqvia abl maintain domin market
share take advantag price-inelast custom
allow gener excess econom profit
long run moreov expect continu demand
healthcar data value-bas reimburs continu
import consider pharmaceut
compani payer iqvia continu expand
emerg market healthcar spend grow
quickli analyt need develop infrastructur
high barrier entri form firm extens
databas difficulti acquir prescript
inform prevent threat new entrant given
iqvia entrench posit healthcar data
analyt space seem like firm exit
rather enter healthcar data space symphoni
materi competitor space
much smaller market share rang solut
limit likelihood displac
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oiqvia leadership posit outsourc
drug commerci allow creat sticki
oth on-going shift outsourc research
develop provid cro industri
steadi growth regardless growth trend global
research develop spend
oth firm less exposur peer
unpredict highli competit early-stag
oiqvia contract sale segment larg no-moat
busi lack competit advantag
oincreas consolid healthcar space could
limit growth iqvia key market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
iqvia appear solid financi health given
combin entiti highli diversifi client base
attract growth prospect anticip
challeng repay debt gener suffici cash
flow end compani approxim
billion total gross debt addit firm nearli
billion cash balanc sheet expect
gener billion oper cash flow
entir cro industri expos chang global
research develop spend rate
outsourc decis pharmaceut biotech firm
believ pharmaceut firm continu outsourc
grow share spend strategi could
chang time budget could constrain
fund macroeconom headwind iqvia one
divers custom base among peer
singl client make sale firm
larg size mean individu trial cancel
minim impact busi result addit
compani im legaci busi could affect data
privaci regul loss key data supplier
exampl initi allow patient opt share
medic record anonym could reach scale
could undermin benefit glean compani
current databas iqvia failur evolv data
technolog platform could also present window
opportun smaller competitor take market share
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
assign iqvia standard stewardship rate
merger late bousbib former im health
ceo board chairman resum posit
combin compani bousbib led im health sinc
hold sever
role unit
technolog think compani capit alloc
rel shareholder-friendli leadership
merger former quintil ceo thoma pike serv
vice chairman presid solut
retir compani coupl month later
pike earli departur rais eyebrow think
cro busi remain steadi hand leadership
 richard staub join quintil
acquisit specialti cro novella clinic
hand
leadership consult
background make sens given
especi quintil increasingli taken strateg
consult role client rather reli
complet task quintil im particip
buy-back program past although focus
tuck-in acquisit round geograph
footprint capabl note high level privat
equiti sharehold largest tpg own roughli
share end third quarter
repres date owner name posit common share held report holder issuer
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
iqvia result track full-year expect
iqvia first-quart perform fell line full-
year expect year result made
materi chang valuat model reflect
new revenu recognit account standard
increas fair valu estim iqvia per share
reflect time valu money wide-moat
rate firm intact -- believ iqvia lead
posit global late-stag contract research industri
like continu long-term thank
unmatch intang asset trial data technolog
growth across board constant currenc basi
iqvia commerci solut segment grew year
year quarter exclud impact
acquisit fall line high-single-digit
growth expect segment typic see
acceler sale back half year due
client spend pattern strong growth iqvia
technolog high-single-digit organ growth real-
compani research develop segment first-
quarter sale expand year year constant
revenu book quarter accord new
revenu recognit account standard augment
contract research busi perform think
compani gain momentum next-gener
cro solut among smaller biopharma client key
busi -- saw sale fall year year constant
currenc anticip
momentum continu iqvia result
increas fve feb
updat fair valu estim iqvia formerli
quintilesim slightli per share follow
compani fourth-quart result gain larg
attribut time valu money quarterli result
outlook prompt major chang
estim amass scale intang asset
iqvia plum posit late-stag contract
research industri healthcar technolog space
underli wide moat rate
although anticip bump fourth-quart sale
firm commerci solut segment thank
season spend pattern technolog growth even
stronger expect year year constant
currenc given pressur top-lin growth
legaci quintil encor busi fulli behind
compani well grow traction seen firm
anticip strong high-single-digit growth
howev softer fourth-quart revenu
iqvia contract research arm partial shadow
out-performance year year constant currenc
weaker book year prior fed fourth
quarter margin weak
momentum net new busi throughout led
iqvia next-gener cro offer expect support
robust growth emerg biotech led adopt
iqvia next-gener solut complex clinic
trial anticip contribut larger biopharma
firm
process expand demand next year result
compani twelve-month trail book-to-bil ratio
swell time support mid-
typic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
singl digit growth expect segment
artifici weigh adopt new account
standard requir revenu recogn
percentag complet basi
integr engag solut larg consist
firm quarter year year
constant currenc compani invest minim
stabil busi tri find buyer
littl expect segment minor
contributor bottom line view compani
focu moatworthi contract research
technolog segment smart strategi expect better
product mix oper leverag top-lin growth
biggest driver modest margin improv
long term
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
